Active Ingredient History
Citrulline (name derived from citrullus, the Latin word for watermelon, from which it was first isolated) is an amino acid. It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. It is also produced from arginine as a by-product of the reaction catalyzed by nitric oxide synthase (NOS) family. Citrulline supplements have been claimed to promote energy levels, stimulate the immune system and help detoxify ammonia (a cell toxin). Citrulline is not involved in protein synthesis. Several pharmacokinetic studies have confirmed that citrulline is efficiently absorbed when administered orally. Oral citrulline could be used to deliver arginine to the systemic circulation or as a protein anabolic agent in specific clinical situations (for example in case of malnourishment), because recent data have suggested that citrulline, although not a component of proteins, stimulates protein synthesis in skeletal muscle through the mammalian target of rapamycin signaling pathway. Citrulline is converted to L-arginine by argininosuccinate synthase. L-arginine is in turn responsible for citrulline's therapeutic effects. Many of L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide (NO). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Lung Injury (Phase 3)
Anemia, Sickle Cell (Phase 1)
Arterial Occlusive Diseases (Phase 1/Phase 2)
Asthma (Phase 2)
Blood Pressure (Phase 1)
Bronchopulmonary Dysplasia (Phase 1)
Cardiovascular Diseases (Phase 1/Phase 2)
Coronary Disease (Early Phase 1)
Diabetes Mellitus, Type 2 (Phase 1)
Eisenmenger Complex (Early Phase 1)
Ethnic and Racial Minorities (Early Phase 1)
Familial Primary Pulmonary Hypertension (Early Phase 1)
Fetal Growth Retardation (Phase 4)
Healthy Volunteers (Phase 1)
Heart Defects, Congenital (Phase 3)
Heart Diseases (Phase 1/Phase 2)
Heart Septal Defects, Atrial (Phase 1/Phase 2)
Heart Septal Defects, Ventricular (Phase 1/Phase 2)
Hypertension (Phase 1/Phase 2)
Hypertension, Pregnancy-Induced (Phase 1)
Hypertension, Pulmonary (Phase 3)
Hypertrophy, Left Ventricular (Phase 1/Phase 2)
Infant, Premature (Early Phase 1)
Infant, Premature, Diseases (Phase 1)
Intermittent Claudication (Phase 2)
Intestinal Failure (Phase 3)
MELAS Syndrome (Phase 1)
Multiple Organ Failure (Phase 3)
Muscular Dystrophies (Phase 2)
Muscular Dystrophy, Duchenne (Phase 3)
Neoplasms (Phase 2)
Obesity (Phase 2)
Peripheral Arterial Disease (Phase 2)
Postpoliomyelitis Syndrome (Phase 3)
Pre-Eclampsia (Phase 2/Phase 3)
Pregnancy (Phase 2/Phase 3)
Premature Birth (Phase 1)
Respiratory Insufficiency (Phase 2)
Sepsis (Phase 3)
Vascular Diseases (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
